COGT (NASDAQ) Form 144 shows proposed 7.0M share sale after conversion
Rhea-AI Filing Summary
Cogent Biosciences reported a Form 144 notice showing proposed sales tied to a conversion: 7,000,000 shares of Common Stock associated with the conversion of Series A Convertible Preferred Stock on 03/31/2026. The filing also records 3,500,000 shares sold on 01/22/2026.
Positive
- None.
Negative
- None.
Insights
Form 144 notice documents proposed and recent secondary sales tied to a preferred conversion.
The filing lists a proposed disposal of 7,000,000 shares of Common Stock arising from the conversion of Series A Convertible Preferred Stock dated 03/31/2026. It also discloses a prior sale of 3,500,000 shares on 01/22/2026.
These are regulatory sale notices; cash‑flow treatment and beneficiary identities are not specified in the excerpt. Subsequent Form 4s or transaction confirmations would provide additional ownership and net‑proceeds details.
Key Figures
Key Terms
Form 144 regulatory
Conversion of Series A Convertible Preferred Stock financial
Issuer financial
FAQ
What does COGT's Form 144 disclosure mean?
Were there recent sales before the Form 144 filing for COGT?
Does the Form 144 excerpt state who receives proceeds from the sale?